Navigation Links
KORRES Q1 2008 Results
Date:5/13/2008

ux de Fonds in Swiss, reaching 17 stores in total abroad while if we incorporate the 2 in Greece, the network is coming up to 19 stores. Group's target for 2008 is to double the number of KORRES stores with the opening of 20 new through the local distributors while at the same time the group will continue to promote KORRES Natural Products through the selective distribution network and Kings & Queens through the semi selective distribution.

In line with the strategic partnerships that the Group maintains and in context with its major growth targets of creating new innovative products by systematically exploiting the Greek Flora, proceeded in the first quarter of 2008, to further enhancement of its corporation with Chios Mastiha Growers Association , by acquiring 5,13% of MEDITERRA, which is the exclusive distributor of Chios Mastiha.

Finally, Group's strategy for 2008 will continue to be the development and promotion of the existing brand KORRES Natural Products as well as the new brand 'Kings & Queens' both in Greece and abroad, focusing its interest mainly on the markets of UK, France, Germany, Spain, US and also China and Russia.

KORRES Natural Products is a rapidly developing Greek company with the aim to utilize its extensive scientific resources for the creation of beneficial and safe products.

The company today offers a complete skin and hair care range, make-up, sun care products and herbal preparations.

Utilizing the experience with 3000 homeopathic remedies, the company today offers more than 500 skin and hair care products and herbal preparations.

The company has already presence in 28 countries at 1,250 POS globally with a goal to become an international brand.

For more information please contact the Head of Group Investor Relations, Ms Athina Lagou, on +30-226-205-4651, or email athina.lagou@korres.com


'/>"/>
SOURCE KORRES Natural Products Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...K, Nov. 21 The general membership ...induct three new individuals at their Annual,Awar...re hotel in New York. A,Lifetime Achievement Awar...into the Medical Advertising Hall of Fame are: , ...r with an account position,at Sudler & Hennes...
(Date:11/21/2008)...ound 2 popular drugs do not cause genetic damage t... 21 (HealthDay News) -- Two popular medications fo...r (ADHD) do not cause genetic damage linked to an ...says. , The study, done by researchers at Duke ...tes of Health, counters a previous one that report...
(Date:11/21/2008)... Nov. 21 In a statewide survey, 33...Institute for Surgery at Presbyterian Hospital of ... annual listing of " Super Doctors ." , , E...ith Key Professional Media, Inc. to survey more th...f Texas to ask, "If you needed medical care, which...
(Date:11/21/2008)... Ind., Nov. 21 Symmetry ... provider of products to the global orthopedic dev...today that Brian S. Moore, President and Chief Exe...ident and Chief Financial Officer, are scheduled t...Care Conference at The New York Palace Hotel on We...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...ovided an insight into how effective the lead petr...ation about the otter species, examination of the ...ing levels of lead pollution in them. The research...l since lead can damage the central nervous system...
...ty of plastic surgeons, 'Plastic Surgery 2006' is ... The convention that is to be held on October 6-1...o is to be attended by more than 6,000 doctors, me...ors in the field of plastic surgery. It is expect...
...ital and Washington University School of Medicine ...ow children under the age of 16 to// use of all-te...a 10-year review of the injuries. Children have n...torized vehicles, and they're driving them on unev...
...with Florida-based Roskamp Institute to conduct a ...ts possible use in Alzheimer's disease. // The Du...riatrics and Old Age Psychiatry from St James’ Hos...ly Memorial Hospital, Loughlinstown, Mater Hospita...
Other Medicine News:Health News:Annual Conference Of Plastic Surgeons In US To Focus On The Future Of Plastic Surgery 2Health News:Call To Ban Use Of ATVs By Children 2
(Date:11/19/2008)... report basic findings on critical enzyme,s regula...reat an array of disorders , , MEMPHIS, Ten... at St. Jude Children,s Research Hospital have gai...y,s enzyme workhorses called calpains. , , ...unction in many cellular processes, including the ...
(Date:11/19/2008)...19 Isogen, a contract development ...g, today announced the first,phase launch of its ...to,specifically address the process, facility and...2 billion highly-niched, low-volume clinical and,...ent. , Companies can invest over $100 milli...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX... and drug development Company,and Sosei Group Co...ading,international biopharmaceutical company, to...rther pivotal pre-clinical efficacy data for NSL-0...l therapy for neuropathic pain and has,successful...
(Date:11/18/2008)...18 Arlington Medical Resources (AM... the pharmaceutical and diagnostic,imaging indust... Privigen was,sold in the U.S. during the third q...ntravenous immune globulin (IVIG) and was launched...created from the blood plasma of thousands,of don...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 150 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 350 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 4SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 1SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 2Prison study to investigate link between diet and behavior 2042 1Prison study to investigate link between diet and behavior 2042 2Carbon monoxide may cause long lasting heart damage 2038 1Carbon monoxide may cause long lasting heart damage 2038 2
...mboEmbolism (VTE) is Reduced by a,Significant 43% ...xane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20,...ounced the publication of the PREVAIL (Prevention,...parin) trial in,the April 21st issue of The Lancet...administration of Clexane(R) / Lovenox(R),(enoxapa...
... 23, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB...ectious disease and dermatology, today announced t...ompany,s antimicrobial,compounds: CSA-8 and CSA-13...rnal of Antimicrobial Agents and Chemotherapy, a,p...ety of,Microbiology, dedicated to advances in the ...
Other Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
The LH 755 simplifies and automates high-volume hematology testing by integrating expert automation and advanced technologies into one workcell. It delivers reliable, accurate results every time. Plu
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C.
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents.
Medicine Products: